Three new crown inactivated vaccines are expected to be available at the end of the year at the earliest
All have entered the phase III clinical stage; the annual production capacity of the three vaccines of the two companies is expected to reach 600 million doses
The domestically-made new crown inactivated vaccine is expected to be available at the end of the year
In the public health and epidemic prevention exhibition area of the Service and Trade Fair, two companies exhibited three inactivated vaccines for new coronary pneumonia.
According to the relevant person in charge of the company, the three vaccines have all entered the phase III clinical stage. If the trial can be launched by the end of the year, the cumulative production capacity of the three vaccines is expected to reach 600 million doses.
China Bio
Two new crown inactivated vaccines have been included in the group to inoculate 50,000 people
At the Sinopharm booth, products such as new coronavirus nucleic acid molecular detection reagents and new coronavirus inactivated vaccines were also all unveiled. Among them, two new coronavirus inactivated vaccines have entered the phase III clinical trial stage.
Luo Linyun, deputy general manager of Sinopharm's China Biological Marketing Center, said that the current inactivated vaccines produced by China Biological have two specifications, one is produced by Wuhan Institute of Biological Products, and the other is produced by Beijing Institute of Biological Products.
At present, the two new crown inactivated vaccines have entered phase III clinical trials, and trials are being carried out in the UAE, Bahrain, Peru, Morocco, Argentina and other countries and regions. The group has been vaccinated up to 50,000 people, and the sample population covers 115 countries. All aspects of progress are leading the world.
In terms of production capacity, according to reports, China National Biotech has established high-level COVID-19 vaccine production workshops in two biological product research institutes in Beijing and Wuhan. The combined annual production capacity of the two workshops can reach 300 million doses.
Prior to this, on July 22 this year, my country has officially launched the emergency use of the new crown vaccine.
Sinopharm China Biotech Covid-19 inactivated vaccine has been approved for emergency use first.
Outside China, these two vaccines have received clinical trial approvals from more than a dozen countries.
"Currently, it mainly depends on the clinical results of Phase III." Luo Linyun said that if the trial goes well, the new crown inactivated vaccine will be officially launched at the end of this year.
There are different strains of the new coronavirus that are circulating around the world. Is the vaccine effective against the virus in all regions?
According to the relevant person in charge of China Biology, scientific researchers have been studying. From the current data, the vaccine can cover the new strains in Beijing, Xinjiang and Europe and other places, and the effectiveness is very good.
Kexing Bio
Completed the construction of production facilities in 100 days with an annual production capacity of over 300 million doses
At the booth of Kexing Holding Biotechnology Co., Ltd., a new type of coronavirus inactivated vaccine-"Kierlai Fu" was also displayed.
At the booth, two packaging forms of "Kierlafor" vaccine were displayed, vial packaging and pre-filled syringe packaging.
The relevant person in charge of the enterprise introduced that the pre-filled syringe packaging is convenient to use, but the transportation cost is high; the vial packaging improves space efficiency, saves transportation costs, and is more economical and practical.
According to reports, Beijing Kexing Zhongwei Biotechnology Co., Ltd. formally launched a new coronavirus vaccine development project called "Crown Crown Action" on January 28 this year. With the support of the joint prevention and control mechanism and the Beijing Municipal Party Committee and Municipal Government, the joint Many cooperating units have made every effort to promote vaccine research and development.
The blind test results show that the vaccine has good safety; the company is currently actively promoting Phase III clinical research with partners in many countries, and it is expected that the trial will be launched by the end of the year.
Kexing Holding Biotechnology Co., Ltd. is a high-tech biotechnology company headquartered in Beijing, currently listed on the Nasdaq Global Select Market.
According to the official website of Kexing Biology, the company has produced China’s first inactivated hepatitis A vaccine, the first pandemic influenza vaccine and the first domestically made influenza virus split vaccine without preservatives. It has also developed the world’s first SARS vaccine. Coronavirus inactivated vaccine (phase I clinical study completed).
The Phase III clinical study of the new coronavirus inactivated vaccine Kellyford developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd. is currently progressing steadily in Brazil, Indonesia and other countries, and the vaccine industrialization construction has also been completed.
The official Weibo of Kexing Holdings once released information that Kexing Zhongwei Biotechnology Co., Ltd. launched the new crown inactivated vaccine industrialization construction project at the end of March this year. Governments at all levels fully coordinated and supported, equipment manufacturers worked together to ensure supply, and construction units continued to work day and night. Tackling tough problems, the new crown vaccine Kerlaifu production base "unconditional admission, 25 days to complete the pre-construction procedures, 100 days to complete the construction of the production workshop and its auxiliary facilities".
Prior to this service trade fair, Kexing Holding Biology had announced through the media that "Kerlaifu" will participate in the service trade fair. In terms of production capacity, after continuous construction, the current production base of Kerrlive has formed an annual output of 3 Production capacity of more than 100 million doses.
There are different strains of the new coronavirus that are circulating around the world. Is the vaccine effective against the virus in all regions?
In late August this year, Yin Weidong, chairman of Kexing Holdings, said in an interview with the media that Kexing had obtained more than 20 strains of viruses, with different sequences, from the United States, Europe, the Middle East, etc., and sera immunized with vaccines. Neutralization, it is found that the virus can be neutralized, indicating that the serotype of the new coronavirus has not changed, and it can be speculated that the vaccine can be protected globally.
Beijing News reporter Sha Xueliang